Online citations, reference lists, and bibliographies.
← Back to Search

Open Access Chemical And Clinical Probes To Support Drug Discovery.

A. Edwards, C. Bountra, D. Kerr, T. Willson
Published 2009 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Drug discovery resources in academia and industry are not used efficiently, to the detriment of industry and society. Duplication could be reduced, and productivity could be increased, by performing basic biology and clinical proofs of concept within open access industry-academia partnerships. Chemical biologists could play a central role in this effort.
This paper references
10.1210/MEND.16.6.0849
Genomics versus orphan nuclear receptors--a half-time report.
T. Willson (2002)
10.1016/0006-291X(86)90008-2
Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase.
T. Tamaoki (1986)
10.1016/j.ccl.2008.06.005
Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
Hemanth Neeli (2008)
10.1046/j.1468-2982.1991.1104175.x
Pain, Tenderness, Wheal and Flare Induced by Substance-P, Bradykinin and 5-Hydroxytryptamine in Humans
K. Jensen (1991)
10.1126/SCIENCE.284.5415.757
Orphan nuclear receptors: shifting endocrinology into reverse.
S. Kliewer (1999)
Substance P levels in the synovium and synovial fluid from patients with rheumatoid arthritis and osteoarthritis.
C. Menkes (1993)
10.1126/SCIENCE.278.5336.275
Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor.
P. Mantyh (1997)
Rebuilding the R&D engine in big pharma.
Jean-Pierre Garnier (2008)
10.1016/0196-9781(89)90006-5
Algesia and local responses induced by neurokinin A and substance P in human skin and temporal muscle
U. Pedersen-Bjergaard (1989)
10.1146/annurev.biochem.78.070907.103305
Large-scale structural biology of the human proteome.
A. Edwards (2009)
10.1016/0306-4522(83)90101-X
Neurotransmitter candidates of somatosensory primary afferent fibres
T. Salt (1983)
10.1016/j.cbpa.2008.01.045
Structural genomics and drug discovery: all in the family.
J. Weigelt (2008)
10.1002/ART.1780330111
Substance P and arthritis: analysis of plasma and synovial fluid levels.
K. Marshall (1990)
10.1073/pnas.0507655102
An index to quantify an individual's scientific research output
J. Hirsch (2005)
10.1016/J.SEMCDB.2007.06.006
MMPs as therapeutic targets--still a viable option?
B. Fingleton (2008)
10.1016/S0140-6736(99)01307-0
Neuropathic pain: aetiology, symptoms, mechanisms, and management
C. Woolf (1999)
10.1016/j.cell.2007.01.021
Chemical Genetics: Where Genetics and Pharmacology Meet
Z. Knight (2007)
10.1126/SCIENCE.294.5548.1866
Nuclear receptors and lipid physiology: opening the X-files.
A. Chawla (2001)
10.1016/j.drudis.2008.11.005
Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.
M. Gunthorpe (2009)
10.1038/nchembio0708-382
Small molecules and chemical tools at the interface.
R. Newman (2008)
10.1053/eujp.1998.0103
Experimental human muscle pain induced by intramuscular injections of bradykinin, serotonin, and substance P
Vladimir Babenko (1999)
10.1517/13543776.18.2.159
Advances in the design and therapeutic use of capsaicin receptor TRPV1 agonists and antagonists
L. Gharat (2008)
Neurotransmitters in action
David Bousfield (1985)
10.1634/THEONCOLOGIST.10-8-565
Development of farnesyl transferase inhibitors: a review.
N. Appels (2005)
10.5055/JOM.2005.0037
Novel Aspects of Pain Management: Opioids and Beyond
R. Barkin (2005)



This paper is referenced by
10.1017/9781316544587.011
Governance of Biomedical Research Commons to Advance Clinical Translation: Lessons from the Mouse Model Community
Tania M. Bubela (2017)
10.1016/j.drudis.2010.06.010
Do technical and commercial biases contribute to the pharmaceutical industry's productivity problems? An analysis of how reordering priorities can improve productivity.
D. Fryburg (2010)
10.1016/j.chembiol.2013.03.004
Structural systems pharmacology: the role of 3D structures in next-generation drug development.
Miquel Duran-Frigola (2013)
10.2139/ssrn.2511602
Intellectual Property, Open Science and Research Biobanks
R. Caso (2014)
10.1371/journal.pmed.1000208
Are Patents Impeding Medical Care and Innovation?
E. R. Gold (2010)
10.4155/fmc.11.85
Drug discovery for neglected tropical diseases at the Sandler Center.
S. Robertson (2011)
10.1016/bs.apha.2020.02.001
Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: A novel tool to probe GLP-1R pharmacology.
F. Willard (2020)
10.1186/1744-8603-10-50
Health diplomacy: a new approach to the Muslim world?
M. Suleman (2014)
10.1016/j.stem.2010.06.010
Commercialization and collaboration: competing policies in publicly funded stem cell research?
T. Bubela (2010)
10.1016/j.tibtech.2010.06.002
Role and reality: technology transfer at Canadian universities.
T. Bubela (2010)
Patents , Public-Private Partnerships or Prizes : How should we support pharmaceutical innovation ?
L. Dan (2009)
10.1038/nrclinonc.2014.153
Clinical cancer research: the past, present and the future
V. Devita (2014)
10.1038/nbt.2284
Combinatorial drug therapy for cancer in the post-genomic era
Bissan Al-Lazikani (2012)
10.1093/nar/gkp937
STITCH 2: an interaction network database for small molecules and proteins
M. Kuhn (2010)
10.1017/S0031182013001121
Open source drug discovery – A limited tutorial
Murray N. Robertson (2014)
Gestion De La Propriété Intellectuelle: Enjeux Et Options Stratégiques (Intellectual Property Management: Policy Issues and Options)
Jeremy de Beer (2011)
10.1021/ml300467n
Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction.
Y. Bolshan (2013)
10.5936/csbj.201303017
The Innovative Medicines Initiative: a Public Private Partnership Model to Foster Drug Discovery
E. Vaudano (2013)
10.17863/CAM.15984
Integration and analysis of protein evolutionary relationships and small molecule bioactivity data
Felix A Kruger (2014)
10.1021/acs.jmedchem.5b01105
An Aggregation Advisor for Ligand Discovery.
John J. Irwin (2015)
10.1002/ardp.201600078
Public–Private Partnerships in Lead Discovery: Overview and Case Studies
M. Gottwald (2016)
10.1021/acs.jmedchem.6b01583
Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies.
Niall Igoe (2017)
10.21955/gatesopenres.1114891.1
An open toolkit for tracking open science partnership implementation and impact [version 1; peer review: awaiting peer review].
E. R. Gold (2018)
10.1371/journal.pcbi.1000530
The Role of Medical Structural Genomics in Discovering New Drugs for Infectious Diseases
W. V. Voorhis (2009)
10.1016/j.drudis.2009.09.011
Visualizing the drug target landscape.
S. J. Campbell (2010)
10.1021/jm201649s
Modern phenotypic drug discovery is a viable, neoclassic pharma strategy.
J. A. Lee (2012)
10.1503/cmaj.100375
New approaches to rewarding pharmaceutical innovation
P. Grootendorst (2011)
10.1038/nnano.2017.1
Raising financing through strategic timing.
E. Maine (2017)
10.1016/B978-0-12-375678-7.01219-0
Patents and Other Incentives for Pharmaceutical Innovation
P. Grootendorst (2014)
Drug discovery for neglected tropical diseases
Stephanie A. Robertson (2011)
10.1007/978-3-642-33116-9_11
Beyond Open Source: Patents, Biobanks and Sharing
E. R. Gold (2013)
10.1021/jm901680b
Selective Inhibitors of the JMJD2 Histone Demethylases: Combined Nondenaturing Mass Spectrometric Screening and Crystallographic Approaches†
N. Rose (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar